OBJECTIVES : SLE (or lupus for short) is a multisystem, complex, autoimmune disease, can present at any age. Lupus can cause damage to the skin, joints, kidneys, brain and lung.The medicines used in the standard treatment of SLE disease are anti-inflammatories and over-the-counter pain relievers, Corticosteroids, Antimalarials, Immunosuppressives (Immune Modulators) and Anticoagulants. The medicines used outside the standard treatment were Belimumab, Mycophenolate Mofetiland Rituximab. The aim of study is to conduct a HTA review of decisions for products indicated in the treatment of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis

METHODS : Considering to the clinical guidelines medicines used outside of standard treatment were determined for systemic lupus erythematosus and lupus nephritis. HTA reports on these drugs were screened and examined on the websites of HTA institutions of United Kingdom (NICE, NIHR), GERMANY (IQWIG, G-BA), FRANCE (HAS), ITALY (AIFA), SPAIN (AquAS, OSTEBA), CANADA (CADTH) and TURKEY (HTA institution not available so Turkey reimbursement agency SGK reports were examined). As a result of the investigations, the suggested indications of institutions, ICER values and prices were reported

RESULTS : Selected countries have issued an HTA report about these three drugs. It has been reported that there were not enough clinical data about these drugs. However, at least 1 of 3 drugs have been recommend by each country. There is one report about belimumab as recommended in United Kingdom, France and Italy. There are two reports about belimumab and Mycophenolate Mofetil as recommended in Germany and Turkey, about Belimumab and Rituximab as recommended in Spain. Also there is not any report about Mycophenolate Mofetil and Rituximab in Canada. However, Canada published 2 reports about Belimumab in 2012 and 2018 as not recommended.

CONCLUSIONS : This research revealed that while HTA reports are based on published data, decisions may wary country to country depending on demographics, culture and politics.